Sponsored
Page 1/2

Pharmaceutical Industry

Life Sciences Field is Booming in Vienna

Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.

October 14, 2015

Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria

Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

August 1, 2014

EU’s Austerity Cuts Adverse to Health

EU’s austerity measures negatively affect citizen’s health, is the result of a health study carried out by “The Lancet”. The Commission was supposed to examine the political effects.

March 27, 2013

Slovakia: CPI Remains Constant

In February, compared with January, consumer prices did not change in total. Increase in prices only in Education, Food and Health Industry.

March 14, 2013

Austria at Medical Fair Asia 2012

Top medical products “made in Austria” at MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA 2012 from September 12 2012 to September 14 2012 in Singapore.

August 20, 2012

U.S. Forest Laboratories Cooperates with Nabriva

The U.S. pharmaceutical company provides funds of $ 25m to the Austrian Nabriva and secures pre-emptory rights.

June 2, 2012

Baxter Enlarges Viennese Site

The U.S. pharmaceutical group makes investments of € 30m in Vienna. The start of operation of a new production facility is planned in 2014.

May 18, 2012

Intercell Completes Equity Private Placement

The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.

May 15, 2012

Intercell Remains in the Loss Area

The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.

May 8, 2012

Canadian Valeant Buys Assets of Gerot Lannach

The Austrian drugmaker Gerot Lannach sells its acetylsalicylic acid business in Russia. The sale price amounts to $ 185m.

March 13, 2012

Sanochemia Announced Scanlux Market Entry in Columbia

The Austrian pharmaceutical company announced the market entry of Scanlux in Columbia. Further approvals are targeted in Costa Rica, El Salvador, Venezuela and Paraguay.

March 7, 2012

Intercell Does Not Leave the Loss zone

The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.

March 6, 2012

Slight Improvement in Sanochemia´s Results

The Austrian pharmaceutical company could increase sales by 12% in the first quarter of 2011/12. Sanochemia could reach small profits again.

February 15, 2012

Intercell Plans to Achieve Turnaround in 2014

The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.

February 6, 2012

Slightly Positive Results at Sanochemia

The Austrian pharmaceutical company raised revenues by 26%. Profits amount to € 0.7m.

January 26, 2012

Too Little Competition for Energy and Pharmaceuticals

According to the Austrian institute of economic research (WIFO), electricity, energy and pharmaceuticals are too expensive.

January 2, 2012

New Chairman for Intercell’s Supervisory Board

Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.

December 30, 2011

Sanochemia Achieves Turnaround

The Austrian pharmaceutical company could turn net results and EBIT into the profit zone. Sales were up too.

December 19, 2011

Intercell Receives Approval for Vaccine in India

The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.

November 10, 2011

Intercell Still Reports Losses

The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.

November 8, 2011

R&D Expenses on the Rise

The largest Austrian Enterprises increased their budgets for research & development by 9.6% on average. This is slightly beyond the global average (9.3%).

October 24, 2011

Intercell Continues Development of Vaccines

The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.

October 24, 2011

Intercell: EU Invests € 30m in Research Program

The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.

September 29, 2011

Intercell Looking for Private Equity Shareholder

According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.

September 27, 2011

Sanochemia´s Purchase of Alvetra & Werfft Completed

The Austrian pharmaceutical group acquires the former subsidiary again for € 5.2m.

September 21, 2011

Intercell Successfully Completes Vaccine Study in India

The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.

September 16, 2011

Intercell: Restructuring Is Progressing

Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

August 16, 2011

ugichem Closes € 2m Financing Round

The Tyrolean biotech company secured funding from two major investors and a research grant from the Austrian Research Promotion Agency.

August 9, 2011

Intercell Is Looking for Financial Investors

The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.

July 19, 2011

Intercell: “We Will Stabilize Our Share Price”

The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.

June 21, 2011

Intercell to Cut Jobs and Research Budget

The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.

June 8, 2011

Sanochemia Confirms the Turnaround and Returns to Profitability

Sanochemia reports a profit and puts the focus on market expansion. Revenue increased by 20 percent year-on-year.

May 13, 2011

Intercell: Sale Is No Longer Ruled Out

The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.

May 11, 2011

Lingelbach New CEO for Intercell

Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.

May 5, 2011

Intercell starts a confirmatory clinical study using the Vaccine Enhancement

Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches

May 4, 2011

Sanochemia: Capital Increase Disappointing

The Austrian pharmaceutical company could not meet its own expectations regarding the capital increase. A strategic investor bailed out.

April 18, 2011

Intercell: Vaccine Development to Suspend

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

April 11, 2011

Intercell Announces next Steps of Development for Pseudomonas Vaccine

Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.

April 2, 2011

Lannacher has Delivery Problems with Iodine Tablets

The Austrian pharmaceutical company manufactures the only potassium iodide tablets in the German-speaking area. Demand strongly exceeds production capacity.

March 18, 2011

Opportunities for Austrian Medical Technology in the UK

An Austrian study showed Austrian buinesses the opportunities offered by the British market: Austrian exports increased by 15% in 2010.

March 17, 2011

Massive Losses for Intercell

The Austrian pharmaceutical company today reported losses for 2010 amounting to € 255m. Operating cash flow has been strongly negative too.

March 2, 2011

Intercell Issues Convertible Bond

The Austrian pharmaceutical company Intercell starts offering of € 30.8m senior convertible debt financing.

February 23, 2011

Sanochemia: Strong Increase in EBIT

The Austrian pharmaceutical company today announced its figures for Q1. Earnings rise eight-fold.

February 18, 2011

Sanochemia Stays in the Red

Despite improvements in its financial data, the Austrian pharmaceutical company Sanochemia does not succeed in eliminating its losses

January 28, 2011

Sanochemia Takes Over Alvetra & Werfft

The Austrian pharmaceutical company Sanochemia strengthens its market position through the acquisition of Alvetra & Werfft GmbH.

January 25, 2011

Pfizer Austria: First Sustainability Report Published

Pfizer Austria published its first sustainability report based on the recognized guidelines of the Global Reporting Initiative.

January 20, 2011

Sanochemia: Decrease in Sales, Decrease in Losses

The Vienna Stock Exchange listed manufacturer of pharmaceutical products could improve its results slighty.

January 3, 2011

Intercell Raises Authorized Capital

The Management Board of the Austrian biotechnology company is authorized to increase the share capital up to a nominal amount of € 855,000.00.

December 16, 2010

Serious setback for Intercell

The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.

December 14, 2010

Economic Chamber in Tokyo: Biotechnology as an Opportunity

The President of the Vienna Economic Chamber, Brigitte Jank, sees above all great opportunities for Austria in Japanese biotechnology and pharmaceutical industries.

December 6, 2010
Fast News Search